IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children’s oncology group report

Stevens AM, Horton TM, Glasser CL, Gerbing RB, Aplenc R, Alonzo TA, Redell MS. IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children’s oncology group report. Pediatr Hematol Oncol. 2023 Mar;40(2):147-158. doi: 10.1080/08880018.2022.2089790. Epub 2022 Jul 15. PubMed PMID: 35838057; PubMed Central PMCID: PMC10498011.

Pediatric acute myeloid leukemia (AML) is a devastating disease which carries a high relapse rate. Current risk stratification divides children into groups with higher and lower risk of relapse. However, within the group of children classified as being at lower risk of relapse, nearly 30 percent of patients still suffer a relapse.1 Because a second complete remission is often not achievable due to chemo-refractory disease, it is crucial to improve our ability to identify at-risk children and provide them with more intensive upfront therapy, or targeted therapies, to prevent relapses and improve long-term cure rates. Therefore, investigating additional clinical and biological characteristics to optimize risk stratification is critical for future progress in treating pediatric AML.